Operational Highlights
- Following approval by the United States Food and Drug Administration (FDA) in the first quarter to begin clinical trials using PRX302 for the treatment of localized recurrent prostate cancer, the first patient was treated on May 2, 2006.
- Preclinical data was presented at the American Association of Cancer Research (AACR) meeting in April which demonstrated the validity of PRX302 as a treatment for prostate cancer and benign prostatic hyperplasia (BPH).
"We are pleased with the progress of the prostate cancer trial and are on track to complete patient recruitment by year end," stated Dr. Fahar Merchant, President and CEO. "Simultaneously, we are adding considerable value to PRX302 by pursuing the BPH indication, which represents another significant market opportunity."
